Evaluating the safety of MB097 with pembrolizumab in melanoma patients

A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an AntiPD1Containing Immunotherapy

This study is testing if a new treatment called MB097, when used with pembrolizumab, is safe for melanoma patients who haven't responded well to other therapies.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Microbiotica Ltd (Industry-sponsored)
• Drugs / interventions: Radiation, pembrolizumab
• Locations: 19 sites (Dijon and 18 other locations)
• Trial ID: NCT06540391 on ClinicalTrials.gov

What this trial studies

This Phase 1b trial aims to assess the safety and tolerability of MB097 when combined with pembrolizumab in patients with melanoma who have shown primary resistance to anti-PD1 therapy. Participants must have confirmed Stage III or IV cutaneous melanoma and measurable disease after prior PD-1/PD-L1 inhibitor therapy. The study will involve monitoring adverse effects and overall patient response to the treatment combination over a specified period.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with unresectable Stage III or IV cutaneous melanoma who have shown primary resistance to PD-1/PD-L1 inhibitors.

Not a fit: Patients with melanoma who have not received prior PD-1/PD-L1 therapy or those with other types of melanoma may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for melanoma patients who do not respond to existing therapies.

How similar studies have performed: While there have been studies exploring combinations of therapies for melanoma, this specific combination of MB097 and pembrolizumab in patients with primary resistance is novel.

Eligibility criteria

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Must have primary resistant cutaneous melanoma and have experienced disease progression as defined by RECIST v1.1 after receiving at least 6 weeks of exposure to PD-1/PD-L1 inhibitor therapy, generally correlating with 2 complete cycles of PD-1/PD-L1 inhibitor therapy.
* Must have histological or cytological confirmation of Stage III (unresectable) or Stage IV cutaneous melanoma
* Must have radiographically measurable disease per RECIST v1.1
* Must be at least 18 years of age at time of informed consent
* Must provide written informed consent, according to local guidelines, signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analysis
* Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at time of informed consent.
* Must have acceptable organ function, as evidenced by laboratory data prior to first dose of any study drug
* Female patients must not be lactating or pregnant
* Male patients, and female patients of childbearing potential who are at risk of pregnancy must agree to use a highly effective method of contraception
* Must have life expectancy ≥12 weeks after the start of any study drug per Investigator's judgment
* Must be willing and able to comply with the Protocol, scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and all other study procedures.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following

* Any treatment for melanoma following the failure of an aPD-1-containing treatment, i.e., no intervening treatments between aPD-1 failure and enrollment into study;
* Prior therapy with any of the following:

  * Radiation therapy to target lesions within 6 weeks of the first dose of MB097
  * Major invasive surgery, excluding placement of vascular access, within 28 days of the first dose of any study drug
  * Probiotic supplement use within 7 days of the first dose of any study
  * LBP use, including FMT, within 6 months of start of therapy with MB097.
* Active, uncontrolled infection requiring systemic antimicrobial, antiviral, or antifungal therapy.
* Active, uncontrolled, symptomatic brain metastases or leptomeningeal metastases
* Ocular, uveal, acral, or mucosal melanoma
* Prior treatment-related toxicities that have not resolved to Grade 2 or less per NCI CTCAE v5.0;
* Patients with a history of immune-related colitis may be included if symptoms have resolved to Grade 1 or less for at least 14 days prior to screening
* Any history of CTCAE v5.0 immune-related toxicity Grade 3 or greater from prior CPI that is recurrent or steroid-refractory
* Known hypersensitivity to any of the ingredients of the study drug(s) or known hypersensitivity to vancomycin (oral or IV)
* Significant medical conditions which, in the Investigator's opinion, could compromise or interfere with the patient's safety or integrity of the study outcomes
* Severe colitis of any etiology (except colitis associated with treatment with an aPD-1 inhibitor)
* History of another malignancy within 3 years before the first dose of any study drug, or any evidence of residual disease from a previously diagnosed malignancy
* Clinically significant (i.e., active) cardiovascular disease
* Any clinically significant safety concern related to prior CPI therapy
* Active autoimmune disease that required systemic treatment in the past 2 years prior to screening
* History of investigational agent or device use within 4 weeks prior to the first dose of study treatment or current participation in a study of an investigational agent
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or, in the opinion of the Investigator, is considered to not be in the best interest of the patient to participate in the study.

Where this trial is running

Dijon and 18 other locations

• Centre Georges Francois Leclerc — Dijon, France (Recruiting)
• CHU de Lille - Hopital Claude Huriez — Lille, France (Recruiting)
• Centre Leon Berard — Lyon, France (Not_yet_recruiting)
• AP-HM - Hopital de la Timone — Marseille, France (Recruiting)
• HCL Centre Hospitalier Lyon Sud — Pierre-Benite Cedex, France (Recruiting)
• Istituto Europeo di Oncologia — Milano, Italy (Recruiting)
• Istituto Nazionale Tumori IRCCS Fondazione G. Pascale — Napoli, Italy (Recruiting)
• Istituto Clinico Humanitas — Rozzano, Italy (Recruiting)
• Hospital Universitario 12 de Octubre — Madrid, Spain (Recruiting)
• Hospital Universitario Ramon y Cajal — Madrid, Spain (Recruiting)
• South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC — Madrid, Spain (Recruiting)
• Consorcio Hospital General Universitario de Valencia — Valencia, Spain (Recruiting)
• Sussex Cancer Centre — Brighton, United Kingdom (Recruiting)
• Addenbrooke's Hospital — Cambridge, United Kingdom (Recruiting)
• Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom (Recruiting)
• The Royal Marsden NHS Foundation Trust — London, United Kingdom (Recruiting)
• The Christie NHS Foundation Trust — Manchester, United Kingdom (Recruiting)
• Freeman Hospital — Newcastle, United Kingdom (Recruiting)
• Royal Marsden Hospital - Surrey — Sutton, United Kingdom (Recruiting)

Study contacts

• Study coordinator: Clinical Development Team

Conditions Melanoma